Cell-line development enhances biopharmaceutical production capacity and quality, but complex biologics like bsAbs and ADCs present new challenges.

Biotechnology company Leucid Bio announced a strategic collaboration with Syenex, an open-source gene therapy platform firm. Leucid will gain access to Syenex’s VivoCell Platform for in vivo delivery ...

The company is struggling to make ends meet as it loses a major undisclosed client.

Authors explore complexities in scaling gene-therapy production with special attention is to monitoring and enhancing ...

Last week, UK-based pharmaceutical conglomerate AstraZeneca announced a further $2 billion investment at two separate sites within the US state of Maryland. This follows an overarching pledge of $50 ...